Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could less be more? bladder cancer trial tests stopping immunotherapy after tumors vanish

NCT ID NCT07625527

Not yet recruiting Disease control Sponsor: Tianjin Medical University Second Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at people with a very high-risk type of bladder cancer that cannot be fully removed with standard surgery. After initial treatment with immunotherapy and surgery, some patients become tumor-free. The trial then randomly assigns them to either continue immunotherapy for up to a year or switch to active surveillance—regular checkups without further treatment unless the cancer returns. The goal is to see if active surveillance is a safe and effective option, potentially sparing patients from unnecessary side effects and costs.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
PD-1/PD-L1 inhibitor-based systemic immunotherapy
What this could lead to
If active surveillance works as well as continued therapy, patients could avoid months of extra treatment, reducing side effects and healthcare costs while maintaining cancer control.
What could go wrong
This is a Phase 2 trial with 120 participants, so results are preliminary. Active surveillance may lead to higher recurrence rates, and the study may not apply to all bladder cancer patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BLADDER (UROTHELIAL, TRANSITIONAL CELL) CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm non-invasive bladder urothelial carcinoma Non-Muscle Invasive Bladder Neoplasms urinary bladder carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BLADDER (UROTHELIAL, TRANSITIONAL CELL) CANCER NON-MUSCLE INVASIVE BLADDER CANCER

Contacts and locations

Locations

  • General Hospital of Tianjin Medical University

    Tianjin, China

  • The Second Hospital of Tianjin Medical University

    Tianjin, 300000, China

  • Tianjin Hospital

    Tianjin, China

  • Xingtai People's Hospital

    Xingtai, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.